Trials / Unknown
UnknownNCT05409222
Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)
Study of Quality of Life Post Preventive Salpingo-oophorectomy in Healthy BRCA1/2 and PALB2 Mutation Carriers
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
- Sex
- Female
- Age
- 30 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
1. Premenopausal BRCA1 / 2 or PALB2 gene mutation carriers who receive hormone replacement therapy (HRT) after preventive salpingo-oophorectomy (PBSO) have a better quality of sexual, psychological, cardiovascular and bone health than carriers who decline HRT. 2. Premenopausal mutation carriers treated with PBSO who choose HRT have a comparable overall survival and specific survival for breast / gynecological cancer to women who undergo surgery and refuse to receive HRT. 3. Premenopausal mutation carriers treated with PBSO have better overall and specific breast / gynecological cancer survival than non-SOBP carriers.
Conditions
Timeline
- Start date
- 2020-03-12
- Primary completion
- 2023-10-01
- Completion
- 2023-10-01
- First posted
- 2022-06-08
- Last updated
- 2022-06-08
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05409222. Inclusion in this directory is not an endorsement.